优发国际·(中国区)随优而动一触即发-Official website

On November 3, to enhance investors' understanding of publicly listed companies, the "Investors Enter Eyebright Medical—Shareholders' Day" event was successfully held under the guidance of the Beijing Securities Regulatory Bureau. Organized by the Beijing Listed Companies Association and supported by CITIC Securities, CITIC Jinpeng Securities, and CICC, the event was hosted by Eyebright Medical.

Recently, the China Listed Companies Association announced the results of the "2025 Excellent Practice Cases of Internal Control for Listed Companies" selection. Eyebright Medical has been honored with the title of "2025 Excellent Practice Case of Internal Control for Listed Companies" in recognition of its exemplary compliance management and robust internal control system.

Recently, Eyebright Medical received honors in two prestigious evaluations.

On July 16th, the 19th Beijing Invention and Innovation Competition award ceremony was held in Beijing. This event featured nearly 3,000 innovative achievements from across the country, with Eyebright Medical's Loong Crystal™ PR Phakic Intraocular Lens distinguished by winning the gold medal.

On April 21, Eyebright Medical held its 15matchth anniversary celebration at its headquarters in Beijing. Founder, Chairman, and General Manager Dr. Xie Jiangbing gathered with employees to reflect on the company's 15-year journey and look forward to future development.

To strengthen the defense against vision health issues in the community and effectively reduce the incidence of blinding eye diseases, Eyebright Medical recently collaborated with a team of ophthalmology experts from Changping District Hospital in Beijing. They conducted a public welfare science popularization event themed "Clear Vision for the Seniors" in the Huojiaying community of Changping District. This event featured lectures, cataract screenings, and myopia prevention initiatives, providing residents with an accessible opportunity to learn about ocular health.

On March 22, the 2025 Future Science City Science and Technology Innovation Finance Conference was held under the theme "Gathering Financial 'Vitality' to Co-create a New Quality Future." The conference was jointly organized by the Changping District Government of Beijing, the Management Committee of Future Science City, and Beijing State-owned Capital Operation Management Co., Ltd.

Recently, the fifth New Economy Enterprise High-Quality Development Conference, organized by the China Enterprise Evaluation Association, was held in Shanghai. The theme of the conference was "Artificial Intelligence Driving New Economic Development," which facilitated an in-depth exploration of new pathways for economic growth.

On January 6, 2025, the Loong Crystal™ PR phakic intraocular lens (Registration No.: 国械注准20253160001), developed by Eyebright Medical, received approval from the National Medical Products Administration (NMPA) through the Special Review for Innovative Medical Devices. Designed for myopia correction in adults with phakic eyes, this lens marks a significant milestone after years of research and clinical trials, enhancing Eyebright Medical's product pipeline and offering a new option for myopic patients.

On December 24, 2023, the 2024 Beijing Top 100 Enterprises list was released, featuring Eyebright Medical's inaugural inclusion in the Top 100 Manufacturing Enterprises at the 93rd position. The company also ranked 43rd in the Top 100 Specialized and Innovative Enterprises (a 33-spot improvement) and 82nd in the Top 100 High-tech Enterprises (a 12-spot improvement).

Recently, Eyebright Medical and Meituan Health held a signing ceremony under the theme "Strategic Cooperation for Mutual Success." The agreement establishes a strategic partnership focused on in-depth collaboration in areas such as solutions for 24-hour smart contact lens stores, product operations, and digital marketing. Dr. Xie Jiangbing , Chairman of Eyebright Medical, and Li Xiaohui, General Manager of Meituan Health, were present to witness the signing ceremony.

On October 24, the Securities Times announced the winners of the 18th China Listed Company Value Evaluation. Eyebright Medical (688050) was recognized as one of the "Top 30 Value Companies on the Sci-Tech Innovation Board," and Chairman Dr. Xie Jiangbing was awarded the title of "Annual Sci-Tech Pioneer of China Listed Companies."

Eyebright Medical has been awarded the highest rating of Level A in the Shanghai Stock Exchange's evaluation of information disclosure for the 2023 to 2024 period. This recognition marks the company's second consecutive A rating and highlights its commitment to excellence in transparency and regulatory governance, reflecting strong investor relations management and operational integrity.

On September 20, Eyebright Medical was invited to the opening ceremony of the 27th Beijing-Hong Kong Economic Cooperation Forum and Investment Promotion Conference. Notable attendees included Beijing Mayor Yin Yong and Hong Kong Chief Executive John Lee, both of whom delivered speeches at the event.

From September 6 to 10, 2024, Eyebright Medical has participated in the 42nd European Society of Cataract and Refractive Surgeons Congress (ESCRS) showcased its range of self-developed products in cataract surgery, myopia management, and consumer vision care, receiving significant recognition in the global market and reinforcing its commitment to excellence in ophthalmic care. The grand event had attracted over 15,000 participants and facilitating valuable exchanges among leading ophthalmic experts.